Skip to main content

Advertisement

SpringerLink
Log in

mTOR/p70S6K Signal transduction pathway contributes to osteosarcoma progression and patients’ prognosis

  • Original Paper
  • Published:
Medical Oncology Aims and scope Submit manuscript

Abstract

The mTOR/p70S6K signal transduction pathway plays a key role in the regulation of cancer cells’ survival and proliferation. However, its roles in osteosarcoma, which is one of the most rapidly growing sarcomas, remain unknown. This study investigated for the first time the correlation between the mTOR/p70S6K signal transduction pathway in human osteosarcoma and patients’ prognosis. The expression patterns of mTOR and p70S6K in paraffin-embedded specimens gathered from 65 patients with primary osteosarcoma were detected by the method of immunohistochemistry using antibodies against mTOR and p70S6K. Kaplan–Meier survival and Cox regression analyses were performed to evaluate the prognosis of patients. Immunostaining revealed that the mTOR/p70S6K signal transduction pathway is activated in human osteosarcoma. Additionally, positive expression of mTOR and p70S6K proteins was significantly correlated with surgical stage, metastasis pattern and percentage of dead cells of osteosarcoma. Moreover, in univariate analysis, surgical stage, metastasis pattern and percentage of dead cells, mTOR and p70S6K expression showed significant influence on overall survival (OS) and disease-free survival (DFS). In multivariate analysis, surgical stage (IIA vs. IIB/III), metastasis pattern (without vs. with), percentage of dead cells (≥90 vs. <90%), mTOR expression pattern (negative vs. positive) and p70S6K expression pattern (negative vs. positive) were significant for DFS and OS. Our results demonstrate the correlation of mTOR and p70S6K expression patterns with the oncological progression of osteosarcoma patients, suggesting the prognostic significance of the mTOR/p70S6K signal transduction pathway in osteosarcoma patients, which may lay a foundation for making further investigations on the mTOR/p70S6K signal transduction pathway as a potential target for osteosarcoma therapy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

Abbreviations

mTOR:

Mammalian target of rapamycin

p70S6K:

p70 S6 kinase

References

  1. Longhi A, Errani C, De Paolis M. Primary bone osteosarcoma in the pediatric age: state of the art. Cancer Treat Rev. 2006;32:423–36.

    Article  PubMed  Google Scholar 

  2. Chou AJ, Gorlick R. Chemotherapy resistance in osteosarcoma: current challenges and future directions. Expert Rev Anticancer Ther. 2006;6:1075–85.

    Article  CAS  PubMed  Google Scholar 

  3. Ek ETH, Ojaimi J, Kitagawa Y, Choong PFM. Outcome of patients with osteosarcoma over 40 years of age: is angiogenesis a marker of survival? Int Semin Surg Oncol. 2006;3:7–18.

    Article  PubMed  Google Scholar 

  4. Huang J, Zhu B, Lu L, Lian Z, Wang Y, Yang X, et al. The expression of novel gene URG4 in osteosarcoma: correlation with patients’ prognosis. Pathology. 2009;41:149–54.

    Article  CAS  PubMed  Google Scholar 

  5. Zhou Q, Zhu Y, Deng Z, Long H, Zhang S, Chen X. VEGF and EMMPRIN expression correlates with survival of patients with osteosarcoma. Surg Oncol. 2009. doi:10.1016/j.suronc.2009.09.002.

  6. Osaka E, Suzuki T, Osaka S, Yoshida Y, Sugita H, Asami S, et al. Survivin as a prognostic factor for osteosarcoma patient. Acta Histochem Cytochem. 2006;39:95–100.

    Article  CAS  PubMed  Google Scholar 

  7. Inoki K, Corradetti MN, Guan KL. Dysregulation of the TSC-mTOR pathway in human disease. Nat Genet. 2005;37:19–24.

    Article  CAS  PubMed  Google Scholar 

  8. Guertin DA, Sabatini DM. An expanding role for mTOR in cancer. Trends Mol Med. 2005;11:353–61.

    Article  CAS  PubMed  Google Scholar 

  9. Martin DE, Hall MN. The expanding TOR signaling network. Curr Opin Cell Biol. 2005;17:158–66.

    Article  CAS  PubMed  Google Scholar 

  10. Law BK. Rapamycin: an anti-cancer immunosuppressant? Crit Rev Oncol Hematol. 2005;56:47–60.

    Article  PubMed  Google Scholar 

  11. Couch FJ, et al. Localization of PS6 K to chromosomal region 17q23 and determination of its amplification in breast cancer. Cancer Res. 1999;59:1408–11.

    CAS  PubMed  Google Scholar 

  12. Liu L, et al. Rapamycin inhibits cell motility by suppression of mTOR mediated S6K1 and 4EBP1 pathways. Oncogene. 2006;25:7029–40.

    Article  CAS  PubMed  Google Scholar 

  13. Bärlund M, et al. Detecting activation of ribosomal protein S6 kinase by complementary DNA and tissue microarray analysis. J Natl Cancer Inst. 2000;92:1252–9.

    Article  PubMed  Google Scholar 

  14. Heinonen H, Nieminen A, Saarela M, Kallioniemi A, Klefström J, Hautaniemi S, et al. Deciphering downstream gene targets of PI3K/mTOR/p70S6K pathway in breast cancer. BMC Genomics. 2008;9:348–59.

    Article  PubMed  CAS  Google Scholar 

  15. Enneking WF, Spanier SS, Goodman MA. A system for the surgical staging of musculoskeletal sarcoma. Clin Orthop Relat Res. 1980;153:106–20.

    PubMed  Google Scholar 

  16. Salzer-Kuntschik M, Delling G, Beron G, Sigmund R. Morphological grades of regression in osteosarcoma after polychemotherapy-study COSS 80. J Cancer Res Clin Oncol. 1983;106(Suppl):21–4.

    Article  PubMed  Google Scholar 

  17. Pantuck AJ, Seligson DB, Klatte T. Prognostic relevance of the mTOR pathway in renal cell carcinoma. Cancer. 2007;109:2257–67.

    Article  CAS  PubMed  Google Scholar 

  18. Kreuter M, Bieker R, Bielack SS. Prognostic relevance of increased angiogenesis in osteosarcoma. Clin Cancer Res. 2004;10:8531–7.

    Article  PubMed  Google Scholar 

  19. Kaya M, Wada T, Kawaguchi S. Increased pretherapeutic serum vascular endothelial growth factor in patients with early clinical relapse of osteosarcoma. Br J Cancer. 2002;86:864–9.

    Article  CAS  PubMed  Google Scholar 

  20. Workman P. Inhibiting the phosphoinositide 3-kinase pathway for cancer treatment. Biochem Soc Trans. 2004;32:393–6.

    Article  CAS  PubMed  Google Scholar 

  21. Granville CA, Memmot RM, Gills JJ, Dennis PA. Handicapping the race to develop inhibitors of the phosphoinositide 3-kinase/Akt/mammalian target of rapamycin pathway. Clin Cancer Res. 2006;12:679–89.

    Article  CAS  PubMed  Google Scholar 

  22. Fang Y, Vilella-Bach M, Bachmann R, Flanigan A, Chen J. Phosphatidic acid-mediated mitogenic activation of mTOR signaling. Science. 2001;294:1942–5.

    Article  CAS  PubMed  Google Scholar 

  23. Mungamuri SK, Yang XH, Thor AD, Somasundaram K. Survival signaling by notch1: mammalian target of rapamycin (mTOR)-dependent inhibition of p53. Cancer Res. 2006;66:4715–24.

    Article  CAS  PubMed  Google Scholar 

  24. Majumder PK, et al. mTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathways. Nat Med. 2004;10:594–601.

    Article  CAS  PubMed  Google Scholar 

  25. Morgensztern D, McLeod HL. Mcleod. PI3 K/Akt/mTOR pathway as a target for cancer therapy. Anticancer Drugs. 2005;16:797–803.

    Article  CAS  PubMed  Google Scholar 

  26. Harada H, Andersen JS, Mann M, Terada N, Korsmeyer SJ. p70S6 kinase signals cell survival as well as growth, inactivating the pro-apoptotic molecule BAD. Proc Natl Acad Sci USA. 2001;98:9666–70.

    Article  CAS  PubMed  Google Scholar 

  27. Beevers CS, Li F, Liu L, Huang S. Curcumin inhibits the mammalian target of rapamycin-mediated signaling pathways in cancer cells. Int J Cancer. 2006;119:757–64.

    Article  CAS  PubMed  Google Scholar 

  28. Hou G, Xue L, Lu Z, Fan T, Tian F, Xue Y. An activated mTOR/p70S6K signaling pathway in esophageal squamous cell carcinoma cell lines and inhibition of the pathway by rapamycin and siRNA against mTOR. Cancer Lett. 2007;253:236–48.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgments

This study was supported by Hunan Provincial Natural Science Foundation.

Conflict of interest statement

The authors report no conflicts of interest. The authors alone are responsible for the content and writing of the paper.

Author information

Authors and Affiliations

  1. Department of Orthopaedics, Huai’an Hospital, Xuzhou Medical College, Huai’an, People’s Republic of China

    Quan Zhou, Shaoxian Zhang & Jiali Zhao

  2. Department of Spinal Surgery, Xiangya Hospital, Central South University, Changsha, People’s Republic of China

    Zhansheng Deng

  3. Department of Orthopaedics, Xiangya Hospital, Central South University, Changsha, People’s Republic of China

    Yong Zhu & Haitao Long

Authors
  1. Quan Zhou
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Zhansheng Deng
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Yong Zhu
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Haitao Long
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Shaoxian Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Jiali Zhao
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Zhansheng Deng.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Zhou, Q., Deng, Z., Zhu, Y. et al. mTOR/p70S6K Signal transduction pathway contributes to osteosarcoma progression and patients’ prognosis. Med Oncol 27, 1239–1245 (2010). https://doi.org/10.1007/s12032-009-9365-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12032-009-9365-y

Keywords

Search

Navigation